Use of buprenorphine in HIV-infected injection drug users: Negligible impact on virologic response to HAART

M. P. Carrieri, D. Vlahov, P. Dellamonica, H. Gallais, G. Lepeu, B. Spire, Y. Obadia

    Research output: Contribution to journalArticlepeer-review

    Abstract

    Some HIV-infected injecting drug users (IDUs) on drug abuse maintenance treatment have access to highly active antiretroviral therapy (HAART); this raises questions about the effects of individual treatments on the efficacy of HAART. The French Cohort Study of HIV-infected IDUs - MANIF-2000 - allowed one to assess whether buprenorphine differentially impacts efficacy of HAART. Of the 103 HAART-treated patients, (excluding active IDUs and patients on methadone), 20 were on buprenorphine substitution treatment and 83 were ex-IDUs. A linear regression model used the differences in viral load titre before and after treatment initiation, as a dependent variable, and showed that buprenorphine treatment was not significantly associated with viral load trend. This was also the case when adjusting for other potential confounders, and suggests that there is no major short-term influence of buprenorphine on HIV viral load in HAART-treated patients. Copyright (C) 2000 Elsevier Science Ireland Ltd.

    Original languageEnglish (US)
    Pages (from-to)51-54
    Number of pages4
    JournalDrug and alcohol dependence
    Volume60
    Issue number1
    DOIs
    StatePublished - Jul 1 2000

    Keywords

    • Buprenorphine
    • Drug maintenance treatment
    • HIV
    • Injection drug users
    • Viral load

    ASJC Scopus subject areas

    • Toxicology
    • Pharmacology
    • Psychiatry and Mental health
    • Pharmacology (medical)

    Fingerprint Dive into the research topics of 'Use of buprenorphine in HIV-infected injection drug users: Negligible impact on virologic response to HAART'. Together they form a unique fingerprint.

    Cite this